Biotricity (NASDAQ:BTCY) Trading Up 26.2% – Should You Buy?

Biotricity, Inc. (NASDAQ:BTCY)’s stock price traded up 26.2% during mid-day trading on Friday . The stock traded as high as $0.40 and last traded at $0.39. 48,209 shares traded hands during trading, a decline of 20% from the average session volume of 60,134 shares. The stock had previously closed at $0.31.

Analysts Set New Price Targets

Separately, HC Wainwright reaffirmed a “neutral” rating on shares of Biotricity in a research note on Monday, November 18th.

Biotricity Price Performance

The company has a market cap of $9.47 million, a PE ratio of -0.28 and a beta of 1.08. The business has a fifty day simple moving average of $0.32 and a two-hundred day simple moving average of $0.41.

Hedge Funds Weigh In On Biotricity

An institutional investor recently bought a new position in Biotricity stock. AE Wealth Management LLC bought a new position in Biotricity, Inc. (NASDAQ:BTCY) in the second quarter, according to its most recent filing with the SEC. The firm bought 97,751 shares of the company’s stock, valued at approximately $88,000. AE Wealth Management LLC owned approximately 0.45% of Biotricity as of its most recent SEC filing. 3.89% of the stock is owned by institutional investors and hedge funds.

About Biotricity

Biotricity, Inc, a medical technology company, provides biometric data monitoring solutions in the United States. The company focuses on delivery of remote monitoring solutions to medical, healthcare, and consumer markets, including diagnostic and post-diagnostic solutions for lifestyle and chronic illnesses.